| Literature DB >> 30522975 |
Bang-Ping Jiann1, Koichi Nakajima2, Sonali Dighe3, Chad D Harshman-Smith4, Tarek A Hassan3.
Abstract
INTRODUCTION: Management of erectile dysfunction (ED) is beset with assumptions around spontaneity of sexual intercourse, requiring candor between the physician and patient if appropriate treatment is to be implemented. AIM: To evaluate the degree to which men who take ED medications plan for and have sex.Entities:
Keywords: Advance Planning; Erectile Dysfunction; Phosphodiesterase Type 5 Inhibitor; Sexual Habits; Sildenafil; Tadalafil; Vardenafil
Year: 2018 PMID: 30522975 PMCID: PMC6377368 DOI: 10.1016/j.esxm.2018.10.006
Source DB: PubMed Journal: Sex Med ISSN: 2050-1161 Impact factor: 2.491
Respondent demographics and comorbidities
| China (N = 254) | Japan (N = 250) | Taiwan (N = 100) | Overall (N = 604) | |
|---|---|---|---|---|
| Mean age, years (SD) | 48.7 (5.40) | 54.1 (8.01) | 48.2 (6.23) | 50.8 (7.26) |
| Age category, n (%) | ||||
| ≤50 | 168 (66) | 90 (36) | 72 (72) | 330 (55) |
| 51–60 | 81 (32) | 102 (41) | 23 (23) | 206 (34) |
| 61–70 | 5 (2) | 58 (23) | 5 (5) | 68 (11) |
| Comorbidities, n (%) | ||||
| None | 0 | 26 (10) | 3 (3) | 29 (5) |
| Hypertension | 67 (26) | 60 (24) | 63 (63) | 190 (31) |
| High cholesterol | 53 (21) | 52 (21) | 48 (48) | 153 (25) |
| Prostate problems | 110 (43) | 32 (13) | 25 (25) | 167 (28) |
| Depression | 26 (10) | 30 (12) | 17 (17) | 73 (12) |
| Diabetes | 47 (19) | 35 (14) | 30 (30) | 112 (19) |
| Arthritis | 52 (20) | 18 (7) | 35 (35) | 105 (17) |
SD = standard deviation.
Figure 1Frequency of planning sexual intercourse in advance.
Erectile dysfunction medication users who plan sexual intercourse on specific occasions, and planning and dosing interval
| China (N = 253 | Japan (N = 216 | Taiwan (N = 95 | Overall (N=564 | |
|---|---|---|---|---|
| Planning of specific occasions | ||||
| I plan when I am going to have sexual intercourse | 85% | 74% | 57% | 76% |
| There are specific days of the week I plan on having sexual intercourse | 64% | 59% | 44% | 59% |
| There are specific times of the day I plan on having sexual intercourse | 64% | 45% | 39% | 52% |
| Length of time sexual intercourse is planned in advance | ||||
| Up to 1 hour | 21% | 10% | 34% | 19% |
| Up to several hours | 49% | 29% | 38% | 39% |
| Up to 1 day | 27% | 27% | 18% | 26% |
| Up to 1 week | 3% | 19% | 7% | 10% |
| More than 1 week | 0% | 10% | 1% | 4% |
| Don’t know/prefer not to say | 0% | 6% | 2% | 3% |
| Length of time between dosing and sexual intercourse | ||||
| ≤30 minutes | 16% | 8% | 32% | 15% |
| >30 minutes but ≤1 hour | 60% | 47% | 42% | 52% |
| >1 hour but ≤4 hours | 22% | 34% | 22% | 27% |
| >4 hours but ≤8 hours | 2% | 5% | 1% | 3% |
| >8 hours but ≤12 hours | 0% | 2% | 2% | 1% |
| ≥12 hours | 0% | 0% | 1% | 0% |
| Don't know/prefer not to say | 0% | 4% | 0% | 1% |
Includes only patients who indicated in question 4 that they plan for sex at some level, ie, hardly ever/sometimes/always plan a specific time in advance;
Strongly agree or tend to agree.
Frequency of erectile dysfunction medication use in last 3 months
| China (N = 254) | Japan (N = 250) | Taiwan (N = 100) | Overall (N=604) | |
|---|---|---|---|---|
| Any use in last 3 months | ||||
| Sildenafil | 73% | 41% | 67% | 59% |
| Tadalafil | 43% | 41% | 25% | 39% |
| Vardenafil | 44% | 34% | 43% | 40% |
| Other | 45% | 22% | 0% | 28% |
| Most recently used | ||||
| Sildenafil | 51% | 31% | 42% | 45% |
| Tadalafil | 16% | 40% | 15% | 22% |
| Vardenafil | 20% | 18% | 5% | 17% |
| Other | 13% | 11% | 38% | 16% |
Overall satisfaction with erectile dysfunction (ED) medication
| China (N = 254) | Japan (N = 250) | Taiwan (N = 100) | Overall (N=604) | |
|---|---|---|---|---|
| Sildenafil | ||||
| Very satisfied | 27% | 19% | 14% | 22% |
| Fairly satisfied | 68% | 60% | 69% | 65% |
| Tadalafil | ||||
| Very satisfied | 20% | 23% | 14% | 20% |
| Fairly satisfied | 78% | 57% | 64% | 67% |
| Vardenafil | ||||
| Very satisfied | 20% | 20% | – | 20% |
| Fairly satisfied | 68% | 61% | – | 65% |
| Overall – All ED treatments | ||||
| Very satisfied | 25% | 20% | 16% | 22% |
| Fairly satisfied | 69% | 59% | 59% | 63% |
The number of vardenafil users from Taiwan was small (n = 5); none of these patients provided a response to the question on treatment satisfaction.
Figure 2Importance of product attributes among users of erectile dysfunction medication: (A) China; (B) Japan; (C) Taiwan; (D) Overall.